5-MeO-MiPT Freebase Powder

---

5-Methoxy-N-methyl-N-isopropyltryptamine, commonly known as 5-MeO-MiPT or moxy, is a lesser-known psychedelic substance belonging to the tryptamine class. It is chemically related to other tryptamines such as 5-MeO-DMT and 5-MeO-DiPT, and it produces its psychoactive effects through activity at serotonin receptors in the brain.

Historical Background

The synthesis and pharmacology of 5-MeO-MiPT were first reported in 1985 by researchers David Repke and Alexander Shulgin. The effects of this compound in humans were documented in Shulgin's influential book, TiHKAL ("Tryptamines I Have Known and Loved").

Effects and User Experience

Anecdotal reports describe the effects of 5-MeO-MiPT as highly stimulating and mildly entactogenic, with a notable absence of typical psychedelic visual distortions. Many users report strong physical and tactile sensations that enhance libido and sexual pleasure, making it distinct from other psychedelics.

Chemical Structure

5-MeO-MiPT is a synthetic indole alkaloid characterized by a core structure typical of tryptamines, which includes a bicyclic indole heterocycle attached at the R3 position to an amino group via an ethyl side chain. This compound is specifically substituted at the R5 position of its indole heterocycle with a methoxy (MeO) functional group (CH3O−). Additionally, it contains a methyl group and an isopropyl chain bound to the terminal amine (RN) of its tryptamine backbone, making it the N-substituted isopropyl homologue of 5-MeO-DMT.

Pharmacological Mechanism

The psychedelic effects of 5-MeO-MiPT are believed to arise from its efficacy as a partial agonist at the 5-HT2A receptor. Additionally, there has been speculation regarding its potential inhibition of monoamine oxidase (MAO), although this has yet to be scientifically demonstrated. Notably, 5-MeO-MiPT binds most strongly to 5-HT1A receptors and also exhibits significant binding affinity to the serotonin transporter (SERT) and norepinephrine transporter (NET), acting as a moderately potent serotonin-norepinephrine reuptake inhibitor (SNRI). These mechanisms may help explain the numerous anecdotal reports of antidepressant and anxiolytic effects associated with modest doses of this compound.

Administration and Experience

5-MeO-MiPT can be administered via oral ingestion or smoking. When ingested orally, users report that the visual and sensory effects become more pronounced. The experience can be divided into two stages: the first half is characterized by stimulating and entactogenic effects, while the second half resembles the effects of traditional tryptamine psychedelics, such as psilocybin mushrooms or LSD. When smoked, the physically and cognitively stimulating effects are emphasized, providing a different experience compared to oral ingestion.

5-MeO-MiPT Freebase Powder is for research use only and not intended for human consumption!

---

5-MeO-MiPT Freebase Powder stock last updated at: April 2025